Yong Zhu1, Shuai Meng2, Maolin Chen1, Kesen Liu1, Ruofei Jia2, Hong Li1, Huagang Zhu1, Zening Jin3. 1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. 2. Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100029, China. 3. Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100029, China. zening@163.com.
Abstract
BACKGROUND: Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Therefore, the purpose of our study was to investigate the clinical outcomes of CTO-PCI in patients with or without DM. METHODS: All relevant articles published in electronic databases (PubMed, Embase, and the Cochrane Library) from inception to August 7, 2020 were identified with a comprehensive literature search. Additionally, we defined major adverse cardiac events (MACEs) as the primary endpoint and used risk ratios (RRs) with 95% confidence intervals (CIs) to express the pooled effects in this meta-analysis. RESULTS: Eleven studies consisting of 4238 DM patients and 5609 non-DM patients were included in our meta-analysis. For DM patients, successful CTO-PCI was associated with a significantly lower risk of MACEs (RR = 0.67, 95% CI 0.55-0.82, p = 0.0001), all-cause death (RR = 0.46, 95% CI 0.38-0.56, p < 0.00001), and cardiac death (RR = 0.35, 95% CI 0.26-0.48, p < 0.00001) than CTO-medical treatment (MT) alone; however, this does not apply to non-DM patients. Subsequently, the subgroup analysis also obtained consistent conclusions. In addition, our study also revealed that non-DM patients may suffer less risk from MACEs (RR = 1.26, 95% CI 1.02-1.56, p = 0.03) than DM patients after successful CTO-PCI, especially in the subgroup with a follow-up period of less than 3 years (RR = 1.43, 95% CI 1.22-1.67, p < 0.0001). CONCLUSIONS: Compared with CTO-MT alone, successful CTO-PCI was found to be related to a better long-term prognosis in DM patients but not in non-DM patients. However, compared with non-DM patients, the risk of MACEs may be higher in DM patients after successful CTO-PCI in the drug-eluting stent era, especially during a follow-up period shorter than 3 years.
BACKGROUND:Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Therefore, the purpose of our study was to investigate the clinical outcomes of CTO-PCI in patients with or without DM. METHODS: All relevant articles published in electronic databases (PubMed, Embase, and the Cochrane Library) from inception to August 7, 2020 were identified with a comprehensive literature search. Additionally, we defined major adverse cardiac events (MACEs) as the primary endpoint and used risk ratios (RRs) with 95% confidence intervals (CIs) to express the pooled effects in this meta-analysis. RESULTS: Eleven studies consisting of 4238 DMpatients and 5609 non-DMpatients were included in our meta-analysis. For DMpatients, successful CTO-PCI was associated with a significantly lower risk of MACEs (RR = 0.67, 95% CI 0.55-0.82, p = 0.0001), all-cause death (RR = 0.46, 95% CI 0.38-0.56, p < 0.00001), and cardiac death (RR = 0.35, 95% CI 0.26-0.48, p < 0.00001) than CTO-medical treatment (MT) alone; however, this does not apply to non-DMpatients. Subsequently, the subgroup analysis also obtained consistent conclusions. In addition, our study also revealed that non-DMpatients may suffer less risk from MACEs (RR = 1.26, 95% CI 1.02-1.56, p = 0.03) than DMpatients after successful CTO-PCI, especially in the subgroup with a follow-up period of less than 3 years (RR = 1.43, 95% CI 1.22-1.67, p < 0.0001). CONCLUSIONS: Compared with CTO-MT alone, successful CTO-PCI was found to be related to a better long-term prognosis in DMpatients but not in non-DMpatients. However, compared with non-DMpatients, the risk of MACEs may be higher in DMpatients after successful CTO-PCI in the drug-eluting stent era, especially during a follow-up period shorter than 3 years.
Entities:
Keywords:
Chronic total occlusions; Diabetes mellitus; Major adverse cardiac events; Medical treatment; Percutaneous coronary intervention
Authors: Paul Fefer; Merril L Knudtson; Asim N Cheema; P Diane Galbraith; Azriel B Osherov; Sergey Yalonetsky; Sharon Gannot; Michelle Samuel; Max Weisbrod; Daniel Bierstone; John D Sparkes; Graham A Wright; Bradley H Strauss Journal: J Am Coll Cardiol Date: 2012-03-13 Impact factor: 24.094
Authors: Emmanouil S Brilakis; Subhash Banerjee; Dimitri Karmpaliotis; William L Lombardi; Thomas T Tsai; Kendrick A Shunk; Kevin F Kennedy; John A Spertus; David R Holmes; J Aaron Grantham Journal: JACC Cardiovasc Interv Date: 2015-02 Impact factor: 11.195
Authors: Run Du; Rui Yan Zhang; Lin Lu; Ying Shen; Li Jin Pu; Zheng Bin Zhu; Qi Zhang; Jian Hu; Zhen Kun Yang; Feng Hua Ding; Jian Sheng Zhang; Wei Feng Shen Journal: Cardiovasc Diabetol Date: 2018-11-27 Impact factor: 9.951